Table 4 Distribution of objective responses in the 56 patients according to KRAS4A and KRAS4B cmRNA expression and treatment groups.

From: KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab

Variable§

Number of patients (%)

p-values

Responders*

Non-responders**

All patients

 KRAS4A

  High

22 (59.5)

 6 (31.5)

0.08

  Low

15 (40.5)

13 (68.5)

 KRAS4B

  High

24 (64.8)

 7 (36.8)

0.05

  Low

13 (35.2)

12 (63.2)

Chemotherapy/Pembrolizumab

 KRAS4A

  High

 8 (47.0)

 4 (36.6)

0.5

  Low

 9 (53.0)

 7 (63.4)

 KRAS4B

  High

10 (58.8)

 4 (36.6)

0.2

  Low

 7 (41.2)

 7 (63.4)

Pembrolizumab

 KRAS4A

  High

14 (70.0)

 2 (25.0)

0.04

  Low

 6 (30.0)

 6 (75.0)

 KRAS4B

  High

14 (70.0)

 3 (37.5)

0.1

  Low

 6 (30.0)

 5 (62.5)

  1. *Patients with complete or partial response.
  2. **Patients with stable disease or disease progression.
  3. §High and Low expression of the two KRAS isoforms according to the Youden index (see text).
Back to article page